The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM). The present study is a 3-year follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloRd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow-up of 36 months (range 6-55), 236 patients experienced disease progression or died. Median progression-free survival (PFS) and overall survival (OS) were 18.4 and 34 months, respectively. The updated multivariate analyses showed a significant reduction of PFS and OS benefit magnitude only in cases with International Staging System stage III. Major adverse events included grade 3/4 neutropenia (18.5%), anemia (15.4%), lymphocytopenia (12.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 33.9% and 18.9%, respectively. No new safety signals with longer follow-up have been observed. Of 319 patients, 245 (76.7%) reached at least a partial remission. A significantly lower response rate was found in patients previously exposed to lenalidomide. In conclusion, our study confirms that EloRd is a safe and effective regimen for RRMM patients, maintaining benefits across multiple unfavorable subgroups.

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials / Bruzzese, A.; Derudas, D.; Galli, M.; Martino, E. A.; Rocco, S.; Conticello, C.; Califano, C.; Giuliani, N.; Mangiacavalli, S.; Farina, G.; Lombardo, A.; Brunori, M.; Rossi, E.; Antonioli, E.; Ria, R.; Zambello, R.; Di Renzo, N.; Mele, G.; Marcacci, G.; Pietrantuono, G.; Palumbo, G.; Cascavilla, N.; Cerchione, C.; Belotti, A.; Criscuolo, C.; Uccello, G.; Curci, P.; Vigna, E.; Mendicino, F.; Iaccino, E.; Mimmi, S.; Botta, C.; Vincelli, D.; Sgherza, N.; Bonalumi, A.; Cupelli, L.; Stocchi, R.; Martino, M.; Ballanti, S.; Gangemi, D.; Gagliardi, A.; Gamberi, B.; Pompa, A.; Tripepi, G.; Frigeri, F.; Consoli, U.; Bringhen, S.; Zamagni, E.; Patriarca, F.; De Stefano, V.; Di Raimondo, F.; Palmieri, S.; Petrucci, M. T.; Offidani, M.; Musto, P.; Boccadoro, M.; Cavo, M.; Neri, A.; Morabito, F.; Gentile, M.. - In: HEMATOLOGICAL ONCOLOGY. - ISSN 1099-1069. - 40:4(2022), pp. 704-715. [10.1002/hon.3031]

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

Giuliani N.;
2022-01-01

Abstract

The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM). The present study is a 3-year follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloRd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow-up of 36 months (range 6-55), 236 patients experienced disease progression or died. Median progression-free survival (PFS) and overall survival (OS) were 18.4 and 34 months, respectively. The updated multivariate analyses showed a significant reduction of PFS and OS benefit magnitude only in cases with International Staging System stage III. Major adverse events included grade 3/4 neutropenia (18.5%), anemia (15.4%), lymphocytopenia (12.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 33.9% and 18.9%, respectively. No new safety signals with longer follow-up have been observed. Of 319 patients, 245 (76.7%) reached at least a partial remission. A significantly lower response rate was found in patients previously exposed to lenalidomide. In conclusion, our study confirms that EloRd is a safe and effective regimen for RRMM patients, maintaining benefits across multiple unfavorable subgroups.
2022
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials / Bruzzese, A.; Derudas, D.; Galli, M.; Martino, E. A.; Rocco, S.; Conticello, C.; Califano, C.; Giuliani, N.; Mangiacavalli, S.; Farina, G.; Lombardo, A.; Brunori, M.; Rossi, E.; Antonioli, E.; Ria, R.; Zambello, R.; Di Renzo, N.; Mele, G.; Marcacci, G.; Pietrantuono, G.; Palumbo, G.; Cascavilla, N.; Cerchione, C.; Belotti, A.; Criscuolo, C.; Uccello, G.; Curci, P.; Vigna, E.; Mendicino, F.; Iaccino, E.; Mimmi, S.; Botta, C.; Vincelli, D.; Sgherza, N.; Bonalumi, A.; Cupelli, L.; Stocchi, R.; Martino, M.; Ballanti, S.; Gangemi, D.; Gagliardi, A.; Gamberi, B.; Pompa, A.; Tripepi, G.; Frigeri, F.; Consoli, U.; Bringhen, S.; Zamagni, E.; Patriarca, F.; De Stefano, V.; Di Raimondo, F.; Palmieri, S.; Petrucci, M. T.; Offidani, M.; Musto, P.; Boccadoro, M.; Cavo, M.; Neri, A.; Morabito, F.; Gentile, M.. - In: HEMATOLOGICAL ONCOLOGY. - ISSN 1099-1069. - 40:4(2022), pp. 704-715. [10.1002/hon.3031]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2933388
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact